Messenger RNA (mRNA) News and Research

RSS

Mutation-acquiring potential of coronaviruses and efficacies of current COVID-19 vaccines against parent and mutant strains of SARS-CoV-2

Researchers reviewed the antibody resistance exhibited by SARS-CoV-2 variants.

18 Apr 2022

Delivery technologies of mRNA and pDNA for advanced therapeutic applications

Innovation Center of NanoMedicine (Center Director: Prof. Kazunori Kataoka) has announced that Prof. Satoshi Uchida (Principal Research Scientist), who is also Associated Professor of the Kyoto Prefectural University of Medicine, published an article review about non-viral messenger RNA (mRNA) and plasmid DNA (pDNA) delivery by addressing the various delivery technologies of mRNA and pDNA, from basic research to therapeutic and clinical application; Pharmaceutics 2022, 14(4), 810.

15 Apr 2022

Additional booster doses of COVID-19 vaccine help protect solid organ transplant recipients

Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.

13 Apr 2022

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

A recent study illustrated the enhanced distinct clustering of pseudotyped particles (PPs) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant.

12 Apr 2022

CDC report on Omicron infections soon after Delta

A new study identifies ten patients with confirmed SARS-CoV-2 Omicron variant infections within 90 days of a previous Delta variant infection.

10 Apr 2022

Study suggests severe neuroinvasion by SARS-CoV-2 in individuals with alcohol use disorder

Researchers investigated the effect of repeated alcohol exposure and withdrawal on angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, putative regulators of SARS-CoV-2 entry, in discrete brain regions.

4 Apr 2022

Research demonstrates potential of local siRNA delivery as COVID antiviral therapy in the lung

Scientists develop a formulation for the pulmonary administration of siRNA. The aim was to suppress the replication of SARS-CoV-2.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

TMPRSS2 inhibitor found to be a novel and effective therapeutic option against pan-variant SARS-CoV-2 infections

Researchers assessed the efficacy of TMPRSS2 against SARS-CoV-2 variants of concern Alpha, Beta, Gamma, and Delta, in mice and human lung cells.

1 Apr 2022

A summary of SARS-CoV-2 RNA-protein interactome studies

A new study summarized the importance of SARS-CoV-2 ribonucleic acid protein interactomes in the study of RNA viruses.

30 Mar 2022

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Researchers evaluated the neurological complications due to SARS-CoV-2 D614G strain, and variants of concern, Delta and Omicron in a hamster model.

28 Mar 2022

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Researchers applied a previously developed thermostable self-amplifying ribonucleic acid vaccine to COVID-19.

28 Mar 2022

Using CRISPR/Cas to develop biosafety materials

Researchers discuss the use of the highly efficient CRISPR/Cas technologies to identify viral genome sequences for biosafety purposes.

21 Mar 2022

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Researchers discuss the effects of the SARS-CoV-2 non-structural protein 1 (Nsp1), which binds to the ribosomal subunit thus inhibiting translation.

20 Mar 2022

UT Dallas researchers explore origins of chronic pain and the potential for better treatments

An investigation into how human nerve cells differ from animal cells has provided researchers from The University of Texas at Dallas' Center for Advanced Pain Studies with important clues in the pursuit of more effective treatments for chronic pain.

19 Mar 2022

Hypoxia-inducible factors and SARS-CoV-2 manifestations

Researchers assessed the role of hypoxia-inducible factors in SARS-CoV-2 infection, respiratory symptoms, and epithelial damage.

18 Mar 2022

Clinical utility of Roche assays determined utilizing samples from participants enrolled in a phase 2 trial of the mRNA-1273 vaccine

Researchers quantified the humoral immune response against the mRNA-1273 COVID-19 vaccine using commercially available high throughput assays.

17 Mar 2022

SARS-CoV-2 infection model generated from human tonsil epithelial organoids

Researchers evaluate the feasibility of tonsil epithelial cell-derived organoids as an ex vivo model for studying SARS-CoV-2 infection.

15 Mar 2022

Using mRNA to introduce gene editor into human muscle stem cells

Mutations that lead to muscle atrophy can be repaired with the gene editor CRISPR-Cas9. A team led by ECRC researcher Helena Escobar has now introduced the tool into human muscle stem cells for the first time using mRNA, thus discovering a method suitable for therapeutic applications.

14 Mar 2022

NIH launches Phase 1 clinical trial evaluating three experimental mRNA HIV vaccines

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines.